STOCK TITAN

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.

Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.

Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.

Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.

Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.

Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.

Rhea-AI Summary

Abbott has received FDA approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System, a dissolving stent for arteries below the knee. This breakthrough technology provides a new treatment option for people with chronic limb-threatening ischemia (CLTI) and peripheral artery disease (PAD). The system offers better outcomes compared to balloon angioplasty, which was the previous standard of care. The LIFE-BTK trial demonstrated that the Esprit BTK System reduces disease progression and improves medical outcomes. This innovation addresses the significant burden of disease and treatment options for patients with severe PAD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
-
Rhea-AI Summary
Abbott celebrates the inspiring stories of 11 individuals overcoming cardiovascular conditions at the HeartMates Draft Day event in NYC, hosted by football player Damar Hamlin and champion Tedy Bruschi.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
Rhea-AI Summary
Abbott reported first-quarter 2024 results with sales of $10.0 billion, driven by strong underlying base business performance. Organic sales growth for the underlying base business was 10.8%, marking the fifth consecutive quarter of double-digit growth. The company announced first-quarter GAAP diluted EPS of $0.70 and adjusted diluted EPS of $0.98. Abbott narrowed its full-year 2024 EPS guidance range, projecting full-year diluted EPS on a GAAP basis of $3.25 to $3.40 and adjusted diluted EPS of $4.55 to $4.70. The company also launched new products and received FDA approvals for innovative treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
Rhea-AI Summary
Abbott's TriClip receives FDA approval for treating tricuspid regurgitation, offering a safe and minimally invasive option. The approval follows positive trial results showing significant symptom improvement and quality of life benefits. TriClip is designed to repair leaky tricuspid valves, providing an alternative to high-risk open-heart surgery for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
-
Rhea-AI Summary
Abbott's i-STAT TBI cartridge receives FDA clearance for whole blood use, enabling rapid assessment of mild traumatic brain injury at patient's bedside. Test provides lab-quality results in 15 minutes, expanding testing capabilities beyond traditional healthcare settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
-
Rhea-AI Summary
Abbott (ABT) to release first-quarter 2024 financial results on April 17, with a live webcast of the earnings conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
Rhea-AI Summary
Abbott highlights four key factors for individuals with diabetes to safeguard heart health, emphasizing the importance of prioritizing health over neglecting it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
-
Rhea-AI Summary
Abbott extends partnership with Real Madrid to combat childhood malnutrition and promote healthy habits. The collaboration includes nutrition education, malnutrition screening, and nutritional guidance for athletes, aiming to improve the lives of children globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
partnership
-
Rhea-AI Summary
Abbott announces new data showing improved HbA1c results in Type 2 diabetes patients using GLP-1 medicines with FreeStyle Libre technology. The studies presented at a conference highlight significant benefits of combining these treatments for better glucose management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
Rhea-AI Summary
Abbott (ABT) declares a quarterly common dividend of 55 cents per share, marking the 401st consecutive dividend since 1924. The cash dividend will be paid on May 15, 2024, to shareholders of record on April 15, 2024. Abbott has raised its dividend for 52 years and is part of the S&P 500 Dividend Aristocrats Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
dividends

FAQ

What is the current stock price of Abbott Laboratories (ABT)?

The current stock price of Abbott Laboratories (ABT) is $115.9 as of November 15, 2024.

What is the market cap of Abbott Laboratories (ABT)?

The market cap of Abbott Laboratories (ABT) is approximately 200.2B.

What does Abbott Laboratories specialize in?

Abbott Laboratories specializes in cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.

What are some of Abbott’s recent product launches?

Recent product launches include the PROTALITY™ high-protein nutrition shake and the TriClip™ system for tricuspid valve repair.

How much of Abbott’s sales are generated outside the United States?

Approximately 60% of Abbott’s sales are generated outside the United States.

What is Abbott’s PROTALITY™ brand?

The PROTALITY™ brand is a high-protein nutrition shake designed to support weight loss while preserving muscle mass, addressing global health challenges like obesity.

How does Abbott support global health initiatives?

Abbott supports global health initiatives through strategic partnerships like their collaboration with the Real Madrid Foundation to reduce childhood malnutrition and promote healthy habits.

What is Abbott’s financial performance like?

Abbott has demonstrated robust financial performance, with strong Q1 2024 results and a consistent track record of dividend payouts, evidenced by its inclusion in the S&P 500 Dividend Aristocrats Index.

How many employees does Abbott have?

Abbott employs over 114,000 people worldwide.

Which continuous glucose monitoring system is Abbott known for?

Abbott is known for its FreeStyle Libre continuous glucose monitoring systems, which are widely recognized for their innovation in diabetes management.

What is Abbott's mission?

Abbott's mission is to help people live more fully at all stages of life by developing life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines.

In how many countries does Abbott operate?

Abbott operates in more than 160 countries worldwide.

Abbott Laboratories

NYSE:ABT

ABT Rankings

ABT Stock Data

200.24B
1.73B
0.53%
78.64%
0.81%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
ABBOTT PARK